Document Detail


Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology.
MedLine Citation:
PMID:  23345116     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with Ewing sarcoma family of tumors (ESFT). Data of patients with ESFTs followed up at different cancer centers in Turkey between 2001 and 2010 were retrospectively analyzed. The median age of 114 patients was 26 years (range 14-66). The median follow-up was 20 months (range 1-118 months). Tumor size was between 1.5 and 14 cm (median 8 cm). Eighty-six percent of patients had localized disease at presentation, and 14 % had metastatic disease. Local therapy was surgery alone in 31 % of patients, surgery combined with radiotherapy in 41 % and radiotherapy alone in 18 %. Approximately 70 % of patients were treated with vincristine, doxorubicin, cyclophosphamide and actinomycin-D, alternating with ifosfamide and etoposide every 3 weeks. In patients with localized disease at presentation, the 5-year disease-free survival and overall survival were 60 and 65 %, respectively. At univariate analysis, patients with tumor size ≥8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size ≤8 cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ESFTs are aggressive tumors with a high incidence of local recurrence and distant metastasis. Multimodality treatment consisting of adequate surgical resection, aggressive chemotherapy (VAC alternating with IE) and radiotherapy is recommended for patients with ESFTs.
Authors:
Erkan Arpaci; Tarkan Yetisyigit; Metin Seker; Dogan Uncu; Ummugul Uyeturk; Berna Oksuzoglu; Umut Demirci; Ugur Coskun; Mehmet Kucukoner; Abdurrahman Isıkdogan; Mevlude Inanc; Necati Alkis; Metin Ozkan
Related Documents :
23397746 - New modalities to treat laryngeal cancer.
23604236 - Ocular adnexal maltomas: case series of patients treated with primary radiation.
24114756 - Using the molecular classification of glioblastoma to inform personalized treatment.
76506 - Malignant lymphoma, small lymphocytic type: a clinicopathologic study of 84 cases with ...
17637516 - Results of surgical treatment of carcinoma of papilla of vater.
7071826 - Cytosine arabinoside bladder instillation therapy for bladder tumors.
Publication Detail:
Type:  Journal Article     Date:  2013-01-24
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  469     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Sakarya Training and Research Hospital, Sakarya, Turkey, doktorerkan2001@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negat...
Next Document:  Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese p...